V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240012661 | 240008867 | 0 | 82.2 | Disease modification (D) | 2017-07-26 | 2017-08-17 | CYCLOPHOSPHAMIDE + VINBLASTINE | N | N | 240021702 | OFATUMUMAB |
| 240012662 | 240008867 | null | null | Palliative (P) | 2017-03-18 | 2017-04-01 | CARBOPLATIN + RT | 2 | N | 240021702 | RUXOLITINIB |
| 240012663 | 240008871 | null | 51.8 | Curative (C) | null | 2016-01-31 | CISPLATIN + FLUOROURACIL + RT | N | N | 240021767 | REMODL TRIAL |
| 240012664 | 240015462 | 1.74 | 96.8 | Palliative (P) | 2016-09-15 | 2016-09-18 | Carboplatin + Topotecan | 02 | N | 240021787 | TOPOTECAN |
| 240012665 | 240008872 | 1.75 | null | null | 2016-12-14 | 2016-12-29 | PEMBROLIZUMAB | null | N | 240021787 | CISPLATIN + GEMCITABINE + RITUXIMAB |
| 240012666 | 240008873 | 1.57 | 86 | Palliative (P) | 2014-05-24 | 2014-05-24 | Irinotecan + Modified De Gramont | 02 | N | 240021810 | CAPECITABINE |
| 240012668 | 240008875 | 1.57 | 82 | Palliative (P) | 2014-05-20 | 2014-05-20 | AML 19 TRIAL | 02 | N | 240022028 | CLOFARABINE + CYTARABINE |
| 240012669 | 240008877 | null | 46.8 | null | 2015-02-02 | 2015-07-10 | CAV | N | N | 240022028 | IFOSFAMIDE |
| 240012670 | 240012743 | 1.68 | 57 | Palliative (P) | 2018-07-19 | 2018-07-19 | R-CHOEP | 02 | N | 240022100 | BORTEZOMIB + THALIDOMIDE |
| 240012671 | 240008879 | 1.8 | 77.5 | Curative (C) | 2017-07-05 | 2017-07-24 | CISPLATIN + GEMCITABINE | N | N | 240022117 | R-EPOCH |
| 240012672 | 240012744 | 0 | 44 | Curative (C) | 2016-04-06 | 2016-04-13 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA | 2 | N | 240022121 | UKALL60+ |
| 240012673 | 240008883 | 1.8 | null | Palliative (P) | 2016-07-28 | 2016-10-01 | CYTARABINE + METHOTREXATE | N | N | 240022133 | IVAC |
| 240012674 | 240012746 | 1.76 | 77.4 | Curative (C) | 2018-07-25 | 2018-07-31 | BORTEZOMIB + THALIDOMIDE | 2 | N | 240022183 | IMATINIB |
| 240012675 | 240012746 | null | 82.5 | Palliative (P) | 2018-07-22 | 2018-07-22 | AML18 PILOT TRIAL | 2 | N | 240022183 | RCEOP |
| 240012676 | 240012746 | 1.58 | 53 | Palliative (P) | 2018-11-01 | 2018-11-02 | Cisplatin + Paclitaxel | 02 | N | 240022183 | AML17 TRIAL |
| 240012677 | 240008884 | 1.82 | 93.7 | Palliative (P) | 2018-04-03 | 2018-04-16 | Cytarabine HD + Methotrexate HD | 2 | N | 240022298 | R CODOX-M/ R IVAC |
| 240012678 | 240008884 | 1.65 | null | null | 2017-12-15 | 2017-12-17 | CVP | 02 | N | 240022298 | EC |
| 240012679 | 240008885 | 1.66 | 0 | Curative (C) | 2014-05-01 | 2014-05-27 | Escalated BEACOPP | N | N | 240022426 | GEMCITABINE + OXALIPLATIN + RITUXIMAB |
| 240012680 | 240008886 | 1.85 | null | Curative (C) | 2013-07-29 | 2013-07-30 | BEAM + FLUDARABINE | N | null | 240022497 | GEMCITABINE + IFOSFAMIDE + VINORELBINE |
| 240012681 | 240008888 | null | null | Adjuvant (A) | 2013-02-19 | 2013-02-23 | CARBOPLATIN + RT | N | N | 240022512 | IVE |
| 240012682 | 240012749 | 1.66 | 90 | Adjuvant (A) | 2017-08-22 | 2017-08-29 | FEC 100 + DOCETAXEL + TRASTUZUMAB | N | N | 240022512 | DOCETAXEL + GEMCITABINE |
| 240012683 | 240008893 | 1.8 | 91.5 | Disease modification (D) | 2013-08-01 | 2013-08-10 | PIXANTRONE | null | N | 240022571 | IMATINIB |
| 240012684 | 240008894 | 1.65 | 54.6 | Curative (C) | 2014-11-08 | 2014-11-10 | UKALL14- Ph 1 Induction | N | N | 240022609 | MABCUTE TRIAL |
| 240012685 | 240008896 | 1.77 | 86.7 | Palliative (P) | 2014-05-04 | 2014-05-04 | ICE-R (Cycle 2 onwards) | N | N | 240022659 | BORTEZOMIB + RITUXIMAB |
| 240012686 | 240012751 | 1.58 | null | Disease modification (D) | 2018-01-01 | 2018-01-13 | PMitCEBO-R | null | N | 240022674 | VINCRISTINE |
| 240012687 | 240012751 | 1.88 | 81.6 | Curative (C) | 2018-05-17 | 2018-05-29 | R-GDP | N | null | 240022674 | Y-90 |
| 240012688 | 240008898 | 1.59 | 52.5 | Curative (C) | 2015-12-02 | 2015-12-07 | ETOPOSIDE + IFOSFAMIDE | N | N | 240022676 | AML18 TRIAL |
| 240012689 | 240008899 | 1.58 | 70.8 | Palliative (P) | 2017-03-15 | 2017-03-15 | CAV | N | N | 240022791 | CYCLOPHOSPHAMIDE + DOCETAXEL + TRASTUZUMAB |
| 240012690 | 240008900 | 1.59 | 82.3 | Palliative (P) | null | 2016-08-02 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | 240022810 | GEMTUZUMAB OZOGAMICIN |
| 240012691 | 240008901 | 1.59 | 54.8 | Palliative (P) | 2015-08-31 | 2015-08-31 | TOPOTECAN | N | N | 240022832 | VINCRISTINE |
| 240012692 | 240008903 | 1.55 | 65.9 | Palliative (P) | 2016-02-14 | 2016-10-14 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA | 02 | N | 240022939 | CISPLATIN + FLUOROURACIL |
| 240012693 | 240008903 | 1.74 | 54.2 | Curative (C) | 2016-10-07 | 2017-05-15 | OFATUMUMAB | 02 | N | 240022939 | CYCLOPHOSPHAMIDE + VINBLASTINE |
| 240012694 | 240008905 | 1.65 | 98 | Curative (C) | 2015-09-01 | 2015-09-22 | Cytarabine HD + Methotrexate HD | N | null | 240023081 | LOMUSTINE |
| 240012695 | 240012758 | 1.66 | 67.9 | Disease modification (D) | null | 2017-05-22 | DHAP - R | 02 | N | 240023140 | UKALL60+ |
| 240012696 | 240008908 | 1.72 | null | null | null | 2017-05-17 | Cetuximab 14 day | null | N | 240023188 | IVE-R |
| 240012697 | 240008908 | 1.58 | 70.8 | Palliative (P) | 2017-12-08 | 2018-01-09 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | null | 240023188 | PIXANTRONE |
| 240012698 | 240008910 | 1.69 | 62 | Palliative (P) | 2017-08-13 | 2017-08-13 | CISPLATIN + FLUOROURACIL | 02 | N | 240023200 | CYTARABINE + ETOPOSIDE |
| 240012699 | 240008910 | 1.86 | 120 | Curative (C) | 2015-11-23 | 2015-12-12 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | N | N | 240023200 | IDELALISIB + RITUXIMAB |
| 240012700 | 240008910 | 0 | 94.5 | Curative (C) | 2014-02-15 | 2014-02-15 | ESHAP | 02 | N | 240023200 | CYTARABINE INTRATHECAL |
| 240012701 | 240008910 | 1.62 | 80 | Palliative (P) | 2014-10-26 | 2014-11-03 | ATG + Busulfan + Fludarabine + Thiotepa | N | N | 240023200 | CYCLOPHOSPHAMIDE + ETOPOSIDE |
| 240012702 | 240008913 | 1.69 | 67.2 | Curative (C) | 2016-08-10 | 2016-09-06 | CHOEP | null | N | 240023657 | REMODL TRIAL |
| 240012703 | 240008913 | 1.75 | 95.8 | Adjuvant (A) | 2017-11-15 | 2017-11-15 | CVP | 02 | N | 240023657 | ETOPOSIDE |
| 240012704 | 240008914 | 1.67 | null | null | null | 2016-07-21 | R-GEM-P | null | null | 240023687 | AML18 TRIAL |
| 240012705 | 240008915 | 1.52 | 63 | Curative (C) | 2018-02-06 | 2018-02-11 | Carboplatin + Liposomal Doxorubicin | 2 | N | 240023735 | MITOXANTRONE |
| 240012706 | 240014565 | null | 68 | Palliative (P) | 2014-10-04 | 2014-10-08 | GALLIUM TRIAL | Y | N | 240023735 | GALLIUM TRIAL |
| 240012707 | 240008919 | null | null | null | 2014-10-13 | 2014-10-15 | R ABVD | N | N | 240023752 | GEMCITABINE + OXALIPLATIN |
| 240012708 | 240008922 | 1.63 | 94.9 | Curative (C) | 2016-06-25 | 2016-11-22 | DOXORUBICIN | 02 | N | 240023832 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 240012709 | 240008922 | null | 0 | Palliative (P) | 2014-09-14 | 2014-09-18 | REMODLB TRIAL | N | N | 240023832 | CAPECITABINE + OXALIPLATIN |
| 240012710 | 240008925 | 1.58 | 25 | Disease modification (D) | 2015-12-24 | 2015-12-26 | AML 19 TRIAL | 2 | N | 240023933 | TRIPLE INTRATHECAL |
| 240012711 | 240008925 | null | 107.7 | Palliative (P) | 2017-07-18 | 2017-07-23 | CAV | N | N | 240023933 | DOXORUBICIN |